Gentle, long-lasting disinfectant that removes biofilms without corroding surfaces
Novel, low corrosion, bio-compatible disinfectant with biofilm and residual efficacy
This project is developing a gentle surface disinfectant meant to protect hospital patients from infections like C. difficile and Candida auris by killing biofilms and leaving a lasting effect.
Quick facts
| Grant type | Sbir 2 grant |
|---|---|
| Study type | NIH-funded research |
| Funding institution | Halomine, INC. NIH-funded |
| Lab location | 1 site (Ithaca, United States) |
| Project ID | NIH-11253506 on NIH RePORTER |
What this research studies
They are creating a polymer disinfectant modeled on a natural immune chemical that kills bacteria and Candida auris on hospital surfaces. The active ingredient is an N‑halamine monomer called Avantamine combined with other monomers to improve solubility and reduce corrosion. Laboratory and EPA-protocol tests have shown biofilm-killing activity, residual protection, no skin irritation, and no metal or plastic corrosion at effective concentrations. This Phase IIB work will finish development and testing to support EPA claims and potential hospital pilot use.
Who could benefit from this research
Good fit: Patients receiving care in hospitals or long-term care facilities where surface-transmitted infections such as C. difficile or C. auris are a risk, and facilities willing to pilot new disinfectants, would be most relevant to this work.
Not a fit: People treated only outside healthcare settings or whose infections are not linked to contaminated surfaces are unlikely to receive direct benefit from this product.
Why it matters
Potential benefit: If successful, this disinfectant could reduce hospital-acquired infections by providing longer-lasting surface protection against bacteria, fungi, and biofilms.
How similar studies have performed: Other chloramine-style and residual surface disinfectants have shown lab effectiveness and some field success, and this compound has matched standard disinfectants in lab and EPA residual testing though broader hospital trials remain limited.
Where this research is happening
Ithaca, United States
- Halomine, INC. — Ithaca, United States (Active)
Researchers
- Principal investigator: Nkemngong, Carine — Halomine, INC.
- Study coordinator: Nkemngong, Carine
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page below.